Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
Posted in RSI News
More RSI News
Dr. Mattison chairs NAM report
Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics. Over the past half-century – with the…
Read News ItemCountry Foods Forum
Leading up to February 11 and 12, 2020, Risk Sciences International had the privilege of assisting Health Canada in its organization of the Country Foods…
Read News ItemWorkshop on Evidence Integration December 5-6, 2019
Risk Sciences International is organizing a two day Workshop on Evidence Integration in support of human health risk assessment in collaboration with the McLaughlin Centre…
Read News ItemRSI wins 2019 Consulting Engineers of Ontario Award of Merit
Risk Sciences International (RSI), as members of a consulting team with Stantec, along with the Ontario First Nations Technical Services Corporation (OFNTSC), has won an Award of Merit from the…
Read News Item